Send to

Choose Destination
Vaccine. 2010 Mar 19;28(14):2624-35. doi: 10.1016/j.vaccine.2010.01.014. Epub 2010 Jan 26.

Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program?

Author information

University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, 3508 GA Utrecht, The Netherlands.


This study assessed whether the inclusion of two rotavirus (RV) vaccines in the Dutch national immunization programme is cost-effective. Costs and outcomes in unvaccinated and vaccinated populations are compared for a time period of 20 years. In the baseline, assuming competitive market forces in relation to vaccine costs, Rotarix is more cost-effective than RotaTeq, resulting in a cost-utility ratio (CUR) of euro 53,000 per DALY (third payer perspective) and euro 49,000 per DALY (societal perspective), but both considered as being not cost-effective. Vaccine-related costs, annual epidemic-size, and indirect protection are the major factors that determine cost-effectiveness of RV vaccination.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center